U.S. regulators put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancer disappear.
The personalized immunotherapy known as CTL019 was developed by the University of Pennsylvania and was designated as a “breakthrough therapy” by the U.S. Food and Drug Administration. This means the experimental therapy will benefit from a speedier than average review process and will get extra attention from the FDA toward development for market. It is the first cancer immunotherapy to receive the breakthrough designation, and only the fifth biologic agent so far. The approach works by extracting a patient’s T-cells, then genetically programming them in the lab to target cancer cells that produce a protein called CD19. The altered T-cells are then re-injected into the patient’s body, where they multiply and attack cancer.
Researchers reported last year that of 27 patients, including 22 children and five adults, with acute lymphoblastic leukemia, 89 percent had a complete response to the therapy, meaning their cancer became undetectable.
In addition to the ongoing trials for acute lymphoblastic leukemia, trials using CTL019 began in the summer of 2010 in patients with relapsed and refractory chronic lymphocytic leukemia.
It is also being tried in patients with non-Hodgkin lymphoma and myeloma. More research is also under way into therapies for mesothelioma, ovarian, breast and pancreatic cancers.